We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

127 hedge funds and large institutions have $872M invested in Avidity Biosciences in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,513% more call options, than puts

Call options by funds: $2.31M | Put options by funds: $24K

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

15% more capital invested

Capital invested by funds: $757M → $872M (+$115M)

10% more funds holding

Funds holding: 115 → 127 (+12)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.33% less ownership

Funds ownership: 104.79% → 102.46% (-2.3%)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
43
Reduced
31
Closed
13
Calls
$2.31M
Puts
$24K
Net Calls
+$2.28M
Net Calls Change
-$1.18M

Top Buyers

1
CAC
Cowen and Company
New York
+$29.2M
2
APM
Avidity Partners Management
Texas
+$9.94M
3
Goldman Sachs
Goldman Sachs
New York
+$8.33M
4
RI
RTW Investments
New York
+$7.19M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.28M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$51.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.6M
3
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.4M
4
GPP
Great Point Partners
Connecticut
-$7.26M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$84.4M +$7.19M +375,784 +8%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$84.4M -$51.9M -2,714,102 -34%
BlackRock
3
BlackRock
New York
$67.3M +$3.63M +189,975 +5%
CAC
4
Cowen and Company
New York
$61.9M +$29.2M +1,524,216 +67%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$56.7M -$6.44M -336,804 -9%
EC
6
EcoR1 Capital
California
$47.3M +$2.67M +139,780 +5%
T. Rowe Price Investment Management
7
T. Rowe Price Investment Management
Maryland
$45.3M +$53.1M +2,775,292 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$44.1M +$5.28M +276,254 +11%
APM
9
Avidity Partners Management
Texas
$42.5M +$9.94M +519,800 +25%
Federated Hermes
10
Federated Hermes
Pennsylvania
$40.5M +$67K +3,500 +0.1%
RCM
11
RA Capital Management
Massachusetts
$35.4M – – –
CAM
12
Cormorant Asset Management
Massachusetts
$32.9M – – –
State Street
13
State Street
Massachusetts
$28.7M -$1.48M -77,344 -4%
ACA
14
Avoro Capital Advisors
New York
$23.7M +$2.87M +150,000 +12%
BC
15
Boxer Capital
California
$18.3M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$15.3M +$1.74M +90,923 +11%
ACM
17
Alethea Capital Management
Washington
$13.6M – – –
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$10.8M +$2.87M +149,768 +29%
Goldman Sachs
19
Goldman Sachs
New York
$10.1M +$8.33M +435,617 +238%
Northern Trust
20
Northern Trust
Illinois
$7.85M +$459K +23,994 +5%
Artisan Partners
21
Artisan Partners
Wisconsin
$6.38M -$46.2K -2,413 -0.6%
5VM
22
5AM Venture Management
California
$6.38M – – –
OCA
23
Octagon Capital Advisors
New York
$6.2M +$1.11M +57,988 +18%
Charles Schwab
24
Charles Schwab
California
$6.16M +$758K +39,639 +12%
Walleye Capital
25
Walleye Capital
New York
$4.42M -$26.8K -1,399 -0.5%
1
2 3 4 5

RNAM Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2022, worth a combined $872M — up 15% from $757M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 13 closed out — a net gain of 12 holders — while 43 added to existing stakes and 31 trimmed.

The largest buyer was Cowen and Company, adding an estimated $29.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $51.9M.

  • 127 institutional investors held Avidity Biosciences (RNAM) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $872M of Avidity Biosciences stock for Q3 2022, up 15% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q3 2022 and 13 closed out, a net change of +12 holders.
  • The largest Avidity Biosciences buyer in Q3 2022 was Cowen and Company, an estimated $29.2M added.
  • The largest Avidity Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $51.9M sold.

Based on aggregated 13F filings for Q3 2022.